Ko8jhxefrg0q5kv9y5if abzena

Abzena

Babraham, GB

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).

Abzena has not listed any services.

Ask A Question Find what you're looking for? If not, you can ask this lab a question:
Antibody Fragment Production
Price on request
Request a quote for more information about this service.
Biopharmaceutical Manufacturing
Price on request

Contract process development and GMP manufacturing of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies

Contract process development and GMP manufacturing of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies

« Show less
Protein PEGylation
Price on request

Abzena offers a range of technologies for the site-specific conjugation of polyethylene glycol (PEG) or other polymers to therapeutic proteins and peptides. The conjugation of PEG (PEGylation) is a well-established method for extending the half-life and thus duration of action of therapeutic proteins, including antibody... Show more »

Abzena offers a range of technologies for the site-specific conjugation of polyethylene glycol (PEG) or other polymers to therapeutic proteins and peptides. The conjugation of PEG (PEGylation) is a well-established method for extending the half-life and thus duration of action of therapeutic proteins, including antibody fragments.

We provide a range of PEGylation technologies which can be used with different molecular weight PEGs, in linear and branched formats. They have been designed to conjugate PEG to either disulfide bonds, thiols on single cysteines or to poly-histidine motifs.

TheraPEG™ – Disulfide conjugation

TheraPEG™ is a conjugation technology for site-specific PEGylation at solvent-accessible disulfide bonds. Most proteins contain disulfide bonds so there is no need to re-engineer the protein prior to PEGylation.

The TheraPEG™ conjugation process involves disulfide bond reduction prior to conjugation but unlike conjugation using maleimide chemistry the bond is re-bridged as part of the conjugation process thereby restoring the tertiary structure of the protein. Site-specific conjugation using TheraPEG™ reduces the heterogeneity of the conjugate, produces a stable product and, because the conjugation process is efficient and predictable, minimises reagent use.

HiPEG™ – Histidine conjugation

HiPEG™ is a conjugation technology for site-specific PEGylation at histidine sequences expressed within or at the N or C terminal ends of a protein. Conjugation at the terminus of the protein can have the advantage of reducing the shielding effect of the PEG on the functional part of the protein thereby minimising the effect on its activity. A histidine tag added to the terminus of a protein to facilitate purification can be used as the conjugation site without interfering with its use for purification of the conjugate.

HiPEG™ has been used to conjugate branched, single and multiple linear PEG molecules to a diverse range of therapeutic proteins, including cytokines antibody fragments and an increase in half-life in vivo has been demonstrated for these examples.

CyPEG™ – Cysteine conjugation

CyPEG™ is a conjugation technology for site-specific PEGylation at a thiol side-chain on a free cysteine. The thiol residue on a cysteine readily undergoes selective and efficient conjugation. CyPEG™ can be used over a wide pH range and results in a more stable conjugate than can be produced using maleimide conjugation chemistry. Proteins or peptides that do not have a cysteine can be engineered to provide a site for site-specific conjugation using CyPEG™.

« Show less
Bioanalytical Assays
Price on request

Abzena’s bioanalytics and bioassay services are specifically designed to help you during the protein or antibody engineering phase of your project. We offer a comprehensive suite of bioanalytical and bioassay techniques to help guide you through the drug discovery phase of your project.

Bioanalytics

Abzena is able to... Show more »

Abzena’s bioanalytics and bioassay services are specifically designed to help you during the protein or antibody engineering phase of your project. We offer a comprehensive suite of bioanalytical and bioassay techniques to help guide you through the drug discovery phase of your project.

Bioanalytics

Abzena is able to perform a wide range of bioanalytical techniques to help you characterise your antibody or protein. Information obtained can help guide your protein engineering strategy and ultimately can aid you in lead candidate selection.

Amongst the methods we offer to help you with antibody assessment and candidate selection are the following:

  • Affinity determination (Biacore)
  • Binding and Competition (flow cytometry, ELISA, HTRF)
  • Intact protein or antibody mass determination (Mass Spec)
  • Peptide mapping including sequence coverage (HPLC, RPMS)
  • Identification of degradation points and instabilities in mAbs (CDR regions) (Mass Spec)
  • Investigation of mAb formulation and serum stability (HPLC, Mass Spec)
  • Thermal unfolding using differential scanning fluorimetry (Sypro Orange))
  • Propensity to aggregation (thermal stress, HPLC, aggregation kit)
  • Identification of site-specific modifications (N– and O-glycosylation, oxidation, deamidation, phosphorylation)

A wide range of additional characterisation techniques are also available and further information can be found in Bioanalytics and Bioassays.

Bioassays

Determining the function of a protein, or ensuring the functional properties have been maintained following engineering are critical steps in the development of your molecule. To help you, Abzena offer a wide range of standard biochemical and biological assays and we can also work with you to develop bespoke assay formats.

The following assays are amongst those currently offered by Abzena:

  • Cell viability/proliferation/cytotoxicity/Apoptisis
  • Internalisation (flow cytometry, fluorescence microscopy)
  • Cell signalling
  • Fc receptor function: ADCC (Antibody Dependent Cell Mediated Cytotoxicity), CDC (Complement Dependent Cytotoxicity)
  • Cell characterisation (drug resistance, differentiation…)

A wide range of additional characterisation techniques are also available and further information can be found in Bioanalytics and Bioassays.

Custom assay development and optimisation

Abzena have significant experience in developing cell based assays to assess function and analytical methods to determine potency, purity, identity, product characterisation and stability. Abzena can develop and optimise protocols to meet your specific requirements.

« Show less
Cell Viability & Proliferation Assays
Price on request
  • Characterise compounds designed to promote or inhibit cell proliferation
  • Assess the cytotoxicity of drugs by measuring dead and/or live cells
  • Interrogate cell death mechanism (apoptosis vs necrosis)

Cell health assays are one of the primary tools to characterise compounds that can impact cell viability or... Show more »

  • Characterise compounds designed to promote or inhibit cell proliferation
  • Assess the cytotoxicity of drugs by measuring dead and/or live cells
  • Interrogate cell death mechanism (apoptosis vs necrosis)

Cell health assays are one of the primary tools to characterise compounds that can impact cell viability or proliferation.
Various assay formats can be used, such as plate-based assays for medium to high throughput or more comprehensive assays using flow cytometry or fluorescence microscopy platforms. Cell health assays are therefore used throughout drug development, from screening of early candidates, to characterisation of lead molecules and drug substance release assays.

Microplate reader-based cell viability, cytotoxicity and apoptosis assays are routinely performed at Abzena.

We also offer to customise and characterise assays to suit particular project needs. Typically, assay optimisation would encompass incubation time and compound concentration evaluation. Various platforms and assay readouts are available, allowing to select the most appropriate method for each study.

Platforms for cell health assays:

  • Fluorescence, luminescence or colorimetric assays compatible with multi-mode microplate readers
  • Cell labelling with specific live/dead cell dyes and apoptotic markers for flow cytometry
  • Stain-free or fluorescence intensity imaging
« Show less
Protein Expression
Price on request

Whether you require 500 μg or 500 mg of antibody or other proteins, we can offer custom antibody and protein production at a range of scales to satisfy your requirements.

Small-scale transient expression of recombinant proteins and antibodies of various isotypes can be performed in HEK cells or alternatively, we also offer both... Show more »

Whether you require 500 μg or 500 mg of antibody or other proteins, we can offer custom antibody and protein production at a range of scales to satisfy your requirements.

Small-scale transient expression of recombinant proteins and antibodies of various isotypes can be performed in HEK cells or alternatively, we also offer both small scale and larger scale transient production in CHO cells without the need for the prior development of stable cell lines.

If you require the production of larger quantities then we can generate research-grade stable protein or antibody-expressing cell lines that can be grown up in 25L Wavebags. As part of the purification process, all our proteins and antibodies undergo rigorous quality control which includes the assessment of purity, and integrity and which can be extended to include endotoxin levels. Please talk to us to discuss your requirements.

« Show less
Therapeutic Monoclonal Antibody (mAb) Development
Price on request

Whether you require 500 μg or 500 mg of antibody or other proteins, we can offer custom antibody and protein production at a range of scales to satisfy your requirements.

Small-scale transient expression of recombinant proteins and antibodies of various isotypes can be performed in HEK cells or alternatively, we also offer both... Show more »

Whether you require 500 μg or 500 mg of antibody or other proteins, we can offer custom antibody and protein production at a range of scales to satisfy your requirements.

Small-scale transient expression of recombinant proteins and antibodies of various isotypes can be performed in HEK cells or alternatively, we also offer both small scale and larger scale transient production in CHO cells without the need for the prior development of stable cell lines.

If you require the production of larger quantities then we can generate research-grade stable protein or antibody-expressing cell lines that can be grown up in 25L Wavebags. As part of the purification process, all our proteins and antibodies undergo rigorous quality control which includes the assessment of purity, and integrity and which can be extended to include endotoxin levels. Please talk to us to discuss your requirements.

« Show less
Antibody Humanization
Price on request

Abzena has many years of experience in humanising antibodies, with numerous antibodies designed using Abzena technology currently in clinical trials. Abzena offers multiple solutions to antibody humanisation suitable for every development path.

Abzena has many years of experience in humanising antibodies, with numerous antibodies designed using Abzena technology currently in clinical trials. Abzena offers multiple solutions to antibody humanisation suitable for every development path.

« Show less
Antibody Affinity Maturation
Price on request

Abzena uses phage display technology to increase the binding affinity of a starting antibody. A typical increase of between 10 and 100-fold can be achieved. The options of screening for potential immunogenicity and providing an antibody that avoids T cell epitopes can be added to an affinity maturation project. Our extensive... Show more »

Abzena uses phage display technology to increase the binding affinity of a starting antibody. A typical increase of between 10 and 100-fold can be achieved. The options of screening for potential immunogenicity and providing an antibody that avoids T cell epitopes can be added to an affinity maturation project. Our extensive experience of bioassay development enables us to routinely isolate antibodies with equivalent binding specificities to the original antibody and with picomolar binding affinities.

Phage Display

For phage display technology, antibodies are first converted to a scFv format. Specific amino acids within the CDRs of the antibody are then targeted for “hotspot” mutagenesis. In addition, specific framework residues may be changed or randomised to increase library diversity. Libraries of mutated genes are then constructed and cloned for display on the surface of the phage. Phage are positively selected against reducing concentrations of target antigen and screened using a range of bioassays as required. Lead scFvs can then be converted to a whole IgG, if required. Once made, the lead antibodies can be characterised using an extensive suite of binding assays (such as using ELISA), affinity determination using Biacore Surface Plasmon Resonance or in an appropriate biological assay.

Directed Evolution

Analogous to affinity maturation, display technologies can also be used to evolve other properties of a molecule, for example, increasing specificity of a molecule to a given receptor over a similar related receptor.

« Show less
Antibody Reformatting
Price on request

As well as altering the Fc portion of an antibody, the variable region of an immunoglobulin can be reformatted into a variety of different fragments such as Fab, F(ab)’2, scFv, VHH, and minibodies, or can be combined with a second specificity to make bispecific antibodies. The smaller antibody formats can be exploited for their... Show more »

As well as altering the Fc portion of an antibody, the variable region of an immunoglobulin can be reformatted into a variety of different fragments such as Fab, F(ab)’2, scFv, VHH, and minibodies, or can be combined with a second specificity to make bispecific antibodies. The smaller antibody formats can be exploited for their improved tumour/tissue penetration and relative ease of expression in non-mammalian systems.

We can re-engineer antibodies and antibody fragments into virtually any format, some of which are shown below. Once produced, the antibodies can be characterised using an extensive suite of assays, such as ELISA, affinity determination using Biacore, or an appropriate biological assay.

« Show less
Antibody Engineering Services
Price on request

Abzena has a long and successful history of providing protein engineering solutions to accelerate biopharmaceutical development and overcome a wide range of challenges. Abzena’s portfolio of antibody and protein engineering services offers a range of standard and custom packages, which include hybridoma sequencing, microbial and... Show more »

Abzena has a long and successful history of providing protein engineering solutions to accelerate biopharmaceutical development and overcome a wide range of challenges. Abzena’s portfolio of antibody and protein engineering services offers a range of standard and custom packages, which include hybridoma sequencing, microbial and mammalian production, antibody humanisation and affinity maturation, protein deimmunisation, biophysical characterisation and custom engineering solutions to achieve specific properties such as bispecificity.

In particular, our proprietary Composite Human Antibody™ platform and Composite Protein™ platforms have a proven track record of supporting our partners take their lead molecule from bench to clinic.

If you have a specific need then contact us to discuss your requirements.

« Show less
Antibody-Drug Conjugate Development
Antibody Drug Conjugate Development
Price on request
  • Benefit from access to Abzena’s wide range of expertise and technology to streamline your ADC development program
  • Complete target to manufacturing service offering for all ADC components including final conjugation
  • Generate a matrix of candidates for ex-vivo assessment before commiting to further development

*Develop a... Show more »

  • Benefit from access to Abzena’s wide range of expertise and technology to streamline your ADC development program
  • Complete target to manufacturing service offering for all ADC components including final conjugation
  • Generate a matrix of candidates for ex-vivo assessment before commiting to further development

Develop a Matrix

At Abzena we understand that there is no one solution to the development of antibody drug conjugates and that every target brings its own set of challenges to development.

Abzena can help guide your development and manufacture of ADCs through testing and characterisation to find the ideal ADC for your patients.

Accelerate ADC Development

Abzena’s customised service’s accelerate the selection of the optimal ADC candidate for your target of interest. Different conjugations technologies can be assessed side by side for efficacy allowing the ability to screen and rank multiple product canidates to optimise your ADC right from the beginning.

Abzena enables you to make an informed decision regarding which conjugation technology is best suited for your target of interest in terms of stability, off -target toxicity and efficacy. In addition you will have piece of mind that the conjugation methods are simple, scalable and reproducible reducing manufacturing and charaterisation costs.

Following screening you can then move into Abzena’s manufacturing stream allowing accelerated production of small batches of non-GMP candidate ADCs.

« Show less
Antibody-Drug Conjugate (ADC) Manufacturing
Price on request

GMP manufacturing of ADC linkers, payloads & combined linker-payloads

  • Up to 15,000L scale GMP mammalian manufacturing using single use technology
  • Extensive experience in non-GMP/GMP chemical manufacturing for ADC’s, payloads and payload-linkers
  • Continually expanding service aiming for full GMP ADC... Show more »

GMP manufacturing of ADC linkers, payloads & combined linker-payloads

  • Up to 15,000L scale GMP mammalian manufacturing using single use technology
  • Extensive experience in non-GMP/GMP chemical manufacturing for ADC’s, payloads and payload-linkers
  • Continually expanding service aiming for full GMP ADC manufacture

Full Manufacturing Support

Moving out of the drug discovery phase and into clinical development requires an increase in the required quantity and quality (cGMP) of your ADC. Abzena’s ADC manufacturing allows you to continue with Abzena for cGMP manufacture of your ADC through clinical trials.

Mammalian Manufacturing

Abzena provides cGMP production and purification for recombinant proteins and antibodies for use in preclinical and phase I and II clinical trials. Abzena has extensive experience in the use of single-use technology which provides flexibility in the production process. The services provided include expression from 1L to 1,000L in batch or fed batch mode and up to 15,000L in perfusion mode through to final fill/finish of Drug Product up to 2000 vial configuration.

Chemical Manufacturing

Abzena’s chemical manufacturing plant in Bristol, PA provides route design and optimisation through to cGMP scale for payloads, cytotoxics and payload linkers depending on HPAPI status.

Antibody Drug Conjugate Manufacturing

Abzena can provide non-GMP manufacturing of full ADCs up to 10g for toxicology studies and is continually investing in and expanding its manufacturing services and aims to offer full cGMP manufacturing for ADCs by Q4 2017.

« Show less
Hybridoma Sequencing
Price on request
  • Sequencing for IgG and IgM monoclonal antibodies
  • Accurate sequencing using specific leader sequence primers

Authentic Sequencing

Abzena’s platform for hybridoma sequencing can determine the DNA and amino acid sequence of your antibody. Sequencing can be performed for IgG and IgM monoclonal antibodies produced by human,... Show more »

  • Sequencing for IgG and IgM monoclonal antibodies
  • Accurate sequencing using specific leader sequence primers

Authentic Sequencing

Abzena’s platform for hybridoma sequencing can determine the DNA and amino acid sequence of your antibody. Sequencing can be performed for IgG and IgM monoclonal antibodies produced by human, mouse and rat hybridoma cell lines.

Having a 100% accurate sequence is crucial, especially if your antibody sequence is to be used for downstream activities such as recombinant antibody production or antibody humanisation. Unlike some methods that can introduce mutations at the start of Framework 1, using primers specifically designed to bind in the leader sequence, Abzena can determine the authentic start to an antibody variable domain. This simple difference can be critical to determining the sequence of a fully functional antibody.. Determining the DNA and amino acid sequence of your preferred antibody can also form a key step to establishing patent protection for your asset.

On the extremely rare occasions where a DNA sequence cannot be obtained, as long as purified antibody is available, then peptide mapping using Mass Spec can be performed to identify the sequence of interest.

« Show less
In vitro Immunogenicity Assays
Price on request

Therapeutic antibodies and proteins can induce an immune response in patients leading to the development of anti-drug antibodies (ADAs). These potentially lead to reduced efficacy through rapid clearance or neutralisation of the drug or toxicity due to cross-reaction with proteins in the body. Although the potential for... Show more »

Therapeutic antibodies and proteins can induce an immune response in patients leading to the development of anti-drug antibodies (ADAs). These potentially lead to reduced efficacy through rapid clearance or neutralisation of the drug or toxicity due to cross-reaction with proteins in the body. Although the potential for immunogenicity of therapeutic antibodies and proteins has been significantly reduced through the application of protein engineering technologies, clinical data shows that many biopharmaceuticals still induce an immune response in patients. It therefore remains a concern for companies developing new products and for the regulatory agencies asked to approve their use.

EpiScreen™ – Ex vivo assessment of immunogenicity
EpiScreen™ is an accurate and sensitive way to assess the potential immunogenicity of proteins and antibodies ex vivo by measuring CD4+ T cell responses, the primary drivers of memory-based immunogenicity. These technologies are used across the industry as a standard for preclinical immunogenicity testing. EpiScreen™ is offered in three assay formats.

EpiScreen™ time course T cell assay

The EpiScreen™ time course T cell assay is widely used to assess the potential immunogenicity of therapeutic antibodies and other proteins before they reach the clinic. Read more >>>

EpiScreen™ DC:T cell assay

The EpiScreen™ DC:T cell assay is used to assess the potential immunogenicity of therapeutic antibodies or other proteins that directly modulate CD4+ T cell activation. Read more >>>

EpiScreen™ T Cell Epitope Mapping

EpiScreen™ T cell epitope mapping identifies the precise number and location of T cell epitopes within an antibody or protein. These can then be eliminated by generating humanized antibodies or deimmunised proteins using our Composite Human Antibody™ or Composite Protein™ technologies. Read more >>>

In silico assessment of immunogenicity
iTope™ and T Cell Epitope Database (TCED™) are in silico tools to rapidly screen antibodies and proteins for potential immunogenicity. Combined, they provide a more accurate prediction of T cell epitopes than other in silico technologies that rely on MHC class II binding analysis alone.

iTope™ and T Cell Epitope Database (TCED™)

Using TCED™ we can screen amino acid sequences from antibodies or proteins against known epitopes (or non-immunogenic sequences) derived from previous EpiScreen™ T cell epitope mapping studies enabling us to more effectively create humanized antibodies and deimmunised proteins. Read more >>>

Assessing the immunogenicity of sub-visible aggregates
The presence of aggregates in biotherapeutics can have a critical effect on the biological activity of the molecule as well as immunogenicity in vivo.

Assessing the immunogenicity of sub-visible aggregates

Abzena can artificially stress proteins to induce the formation of sub-visible aggregates of different properties at quantities that may be present in clinical material (after storage and handling). The stressed antibodies are characterized with an orthogonal analytical approach and compared for their immunogenic potential in vitro..

« Show less
Phage Display Library Construction and Screening
Price on request

Abzena’s phage display technology, using naïve and immune libraries (from a variety of species, including llamas), can be used to identify lead candidates against a vast range of targets, including:

  • GPCR
  • Ion channels
  • Kinases
  • Growth Factors/Receptors
  • TNF superfamily receptors and ligands
  • Blood proteins
    -... Show more »

Abzena’s phage display technology, using naïve and immune libraries (from a variety of species, including llamas), can be used to identify lead candidates against a vast range of targets, including:

  • GPCR
  • Ion channels
  • Kinases
  • Growth Factors/Receptors
  • TNF superfamily receptors and ligands
  • Blood proteins
  • Brain neurology targets
  • Tumour biomarkers
  • Cytokines and receptors
  • Immunoglobulins
  • Toxins
  • Virus
  • T cell activators, ligands and receptors
  • Checkpoint modulators
  • Non protein targets

In phage display technology, antibody fragments (Fabs) are fused to the filamentous bacteriophage M13 gene III coat proteins, thus allowing billions of phages to be produced that each display on their surface an antibody fragment with a unique specificity. These highly diverse phage populations can then be presented to the desired target and, through a process of selection, amplification and re-selection (panning), antibody fragments can be isolated that have high specificity for the antigen.

Due to the flexibility of the phage display-based selection process, this technology enables the identification of antibody fragments with very specific characteristics, representing an alternative to the classical hybridoma technology.

By reducing the concentration of antigen and the use of stringent conditions during panning, Fabs can be selected that have high affinity/potency and are stable. Selection for function, for example antagonism, agonism, internalisation and epitope specificity are also possible.

This technology has been used in projects such as generating mAbs against different domains of llama IgG1 and generating capture and detection mAbs for cancer and heart biomarkers.

Libraries used in phage display include:

Llama VHH Naïve Library

The 1.5 billion llama VHH naïve library was generated using biological samples from ten different animals and can be used to select binders against virtually any antigen. Naïve libraries are ideal for use when immunisations are not appropriate for reasons such as limits to antigen availability, antigen toxicity or where epitopes are immunodominant.

Llama VHH single domain antibodies are stable, resistant to low pH, have high thermostability and have increased hydrophobicity compared to VHHs engineered from other species.

Human Fab Naïve Library

The human library contains over 10 billion Fabs ready for the discovery binders to your target.
The library comprises Fabs rather than single chain variable fragments (scFvs) as is the case for some other human libraries. Abzena can undertake the conversion of selected Fabs to IgG and, compared to scFvs, Fabs are much less prone to aggregation issues and loss of activity when re-formatting, thus improving the chances of delivering the desired target specificities and properties.

« Show less
Compound Synthesis
Price on request

Abzena’s team of experienced organic chemists has produced a variety of complex molecules at mg to kg scale, including: intermediates, drug metabolites, process impurities, degradants, reference compounds, preclinical drug candidates, and other organic molecules for a diverse array of industries.
Abzena’s custom synthesis... Show more »

Abzena’s team of experienced organic chemists has produced a variety of complex molecules at mg to kg scale, including: intermediates, drug metabolites, process impurities, degradants, reference compounds, preclinical drug candidates, and other organic molecules for a diverse array of industries.
Abzena’s custom synthesis expertise includes:
Antibody drug conjugates (ADCs)
Bioconjugate chemistry
Linker chemistry
Asymmetric synthesis and chiral separation
Multi-step synthetic and medicinal chemistry
Natural products including carbohydrates and steroids
Drug metabolites and API impurities
Organometallic chemistry
Peptide and polypeptide synthesis
Highly pure polycyclic aromatic hydrocarbons for material science
Photochemistry and pressure reactions
Stable isotopes including deuterium, 13C and15N
Toxic compounds and potent substances

« Show less
Ex Vivo Models and Assays
Price on request
Request a quote for more information about this service.
NMR
Nuclear magnetic resonance spectroscopy
Price on request

From routine small NMR spectra such as 1D proton, 1D carton, 1D fluorine and 1D phosphate to advance 2D COSY, 2D HMQC, 2D HMB, etc.
From routine peptide NMR spectra to peptide structure determination.
From protein-ligand binding characterization to binding site mapping and protein -ligand complex structure determination
NMR-based drug discovery

From routine small NMR spectra such as 1D proton, 1D carton, 1D fluorine and 1D phosphate to advance 2D COSY, 2D HMQC, 2D HMB, etc.
From routine peptide NMR spectra to peptide structure determination.
From protein-ligand binding characterization to binding site mapping and protein -ligand complex structure determination
NMR-based drug discovery

« Show less
Protein Engineering
Price on request

Protein engineering to create humanized antibodies and deimmunised therapeutic proteins

Protein engineering to create humanized antibodies and deimmunised therapeutic proteins

« Show less
Stable Cell Line Generation
Price on request

Cell line development for the Manufacturing of recombinant proteins and antibodies

Cell line development for the Manufacturing of recombinant proteins and antibodies

« Show less
Biopharmaceutical Process Development
Price on request

Contract process development and GMP manufacturing of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies

Contract process development and GMP manufacturing of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies

« Show less
Chemical Crosslinking/Bioconjugation
Price on request

Proprietary site-specific conjugation technologies and novel payloads for ADC development.

Proprietary site-specific conjugation technologies and novel payloads for ADC development.

« Show less
Immunoassay Development
Price on request

Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products

Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products

« Show less
Synthetic Chemistry
Price on request
Request a quote for more information about this service.
Immunoassays
Price on request
Request a quote for more information about this service.
DNA Sequencing
Price on request
Request a quote for more information about this service.
Chemistry and Materials
Price on request
Request a quote for more information about this service.
Nucleic Acid Services
Price on request
Request a quote for more information about this service.
Spectroscopy
Price on request
Request a quote for more information about this service.
Formulation Services
Price on request
Request a quote for more information about this service.
Pharmacology & Toxicology
Price on request
Request a quote for more information about this service.
Cell and Tissue Culture
Price on request
Request a quote for more information about this service.
Antibody Services
Price on request
Request a quote for more information about this service.
Bioanalysis
Price on request
Request a quote for more information about this service.
Imaging & Spectroscopy
Price on request
Request a quote for more information about this service.
Biology
Price on request
Request a quote for more information about this service.
Protein Services
Price on request
Request a quote for more information about this service.
Cells and Tissues
Price on request
Request a quote for more information about this service.
DNA Services
Price on request
Request a quote for more information about this service.
Manufacturing Services
Price on request
Request a quote for more information about this service.
Cell-Based Assays
Price on request
Request a quote for more information about this service.
Biochemistry & Molecular Biology
Price on request
Request a quote for more information about this service.
2017-08-09 00:46:43 +0100

Net Promoter Score of 8 received for In vitro Immunogenicity Assays.

Additional Ratings: satisfaction with deliverable: 8, satisfaction with timeliness: 9.

Be the first to endorse Abzena

Endorse this lab